Phase 4 N=43 BK Treatment Study
BK Viremia
Primary: Percent Change From Baseline in BK Virus Copies at 3 Months — 70.3; 69.1 Percent change of BK virus copies
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
Phase 4 N=42 Dexamethasone and Pain Following Total Knee Arthroplasty
Acute Pain · Chronic Pain
Primary: Change in Visual Analogue Pain Score — 3.09; 4.80; 3.56; 5.5 units on a scale — p=0.052
Phase 4 N=54 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
Herpes Zoster
Primary: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV — 45; 9 Participants
Phase 4 N=171 A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
Benign Prostatic Hyperplasia
Primary: Percentage of Participants Preferring Combination Therapy Over Alpha Blocker Alone on the Treatment Preference Questionnaire (TPQ) — 44.0; 68.3; 56.0; 31.7 percentage of…
Phase 4 N=205 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Neovacular Age-related Macular Degeneration
Primary: Percent Change From Baseline at Month 3 in Plasma VEGF Following Intravitreal (IVT) Injection of Anti-VEGF Agent — 41.04; -21.53 Percent change — p=0.012
Phase 4 N=87 Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
Coronary Artery Disease
Primary: Lipiscan - Lipid Core Burden Index (LCBI) — 95.4; 132.4; 99.9; 99.8 ratio
Phase 4 N=150 Thoracoabdominal Arortic CTA Study
Thoracic Aortic Aneurysm
Primary: Radiation Dose — 35.1; 25.4; 25.5 mSv
Phase 4 N=338 Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
Cancer
Primary: Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee — 14 participants
Phase 4 N=1,089 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
CML in Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR4^0) at 18 Months — 38.3 Percentage of Participants
Phase 4 N=172 Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
Posttraumatic Stress Disorder · Anxiety Disorder
Primary: Change From Baseline Skin Conductance Response — .06; .17; -1.27; -.04 microSiemens — p=>.05
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 4 N=10 Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions
High Risk Abdominal Wounds
Primary: Number of Participants With Surgical Site Infections Within 1 Month (4 Weeks ) From Index Operation — 1 Participants
Phase 4 N=56 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
Phase 4 N=57 Postoperative Pain Control Following Vitreoretinal Surgery
Retinal Detachment · Proliferative Vitreoretinopathy · Retinoschisis
Primary: Mean Pain Score — 2.9; 3.8 units on a scale